AbbVie's stock falls after lymphoma treatment trial data disappoints

Shares of AbbVie Inc. ABBV, -2.84% fell 2.2% in premarket trade Wednesday, after the biopharmaceutical company said an update on a phase 3 study evaluating the addition of ibrutinib to a chemotherapy regimen failed to meet its primary endpoint of improving event-free survival.